Stähli C, Takacs B, Miggiano V, Staehelin T, Carmann H
Experientia. 1985 Nov 15;41(11):1377-81. doi: 10.1007/BF01949996.
Of 360 mAb obtained in a cell fusion experiment with the spleen cells of a mouse immunized with a mixture of different human breast carcinoma cell lines, 30 mAb were selected which reacted more strongly with tumor cells than with (noncancerous) fibroblasts. These mAb were tested for reactivity with additional types of cancerous and noncancerous tissues. Two mAb showed high tumor selectivity, but the corresponding epitopes on individual tumor cells were heterogeneously expressed. The mAb will be evaluated for in vivo applications.
在用不同人乳腺癌细胞系混合物免疫的小鼠脾细胞进行的细胞融合实验中获得了360种单克隆抗体（mAb），从中选择了30种与肿瘤细胞反应比与（非癌性）成纤维细胞反应更强的mAb。对这些mAb进行了与其他类型癌组织和非癌组织反应性的测试。两种mAb显示出高肿瘤选择性，但单个肿瘤细胞上的相应表位表达不均一。这些mAb将进行体内应用评估。
